🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A set of cancer genomes holds promise for improving the treatment of children with aggressive blood cancers. go.nature.com/3YIPYbu

Great commentary from Giorgia Guglielmi (she/her).

Commentary on our recently published T-ALL cancer genomics research in Nature Genetics by Safia Danovi nature.com/articles/s4158…

More T-ALL non-coding alterations. Rahman et al. identified a distinct non-coding alteration in T-ALL, highlighting a novel 'promoter tether' mechanism involving deleted CTCF site. In our study, we also observed this deletion in 1.2% of cases.

Review article on T-ALL classification and risk stratification out now in @BloodJournal doi.org/10.1182/blood.…

Congratulations to our Scientific Director, Prof. Satu Mustjoki, and her team for being awarded the prestigious #Medix2024Prize for their significant study published in Immunity last year 👏 Join the seminar at 12 in Biomedicum or helsinki.zoom.us/j/61892612947 minervafoundation.fi/media-release-…

Petri Pölönen, Charles Mullighan, and David Trent Teachey highlight ongoing efforts to identify reliable prognostic biomarkers and underscore the potential of genomics-based classification to guide T-ALL treatment strategies. | St. Jude Research bit.ly/3zYB2fm

An insightful summary and commentary on our recent T-ALL genomics study by Yizhou Huang and Charles de Bock: onlinelibrary.wiley.com/doi/10.1002/he…

Excited to share our latest work in Nature Cancer to get a better understanding why relapsed T-ALL is so deadly and potential target strategies, led by Jason Xu and @changya1 with members of David Teachey, @junjyang, Charles Mullighan and many great colleagues. twtr.to/foS9o.

Thankful to @BloodJournal for the opportunity to write a commentary on the elegant study by Sunniyat Rahman and colleagues. ❗️Check it out to learn how the loss of a “promoter tether” induces IRX3 oncogenic activation in T-ALL. Lindsey Montefiori St. Jude Research ashpublications.org/blood/article/…

Out today Journal of Experimental Medicine our collaboration with Mark Chiang and his group (University of Michigan Medical School ) on novel transcriptional circuits defining cardinal features of high-risk acute leukemia (pediatric ALL). From our side our leader was Francesco Boccalatte with help from Giovanni Gambi. #Cancer

Native stem cell transcriptional circuits define cardinal features of high-risk leukemia Journal of Experimental Medicine Iannis Aifantis Francesco Boccalatte doi.org/10.1084/jem.20…

Out today at Nature Immunology our extensive review of the immune micro-environment in human leukemia. Prepared by Zoe and Varvara in the #AifantisLab. Its been a decade-long trip to demonstrate that -like solid tumors- leukemia has specific niches in tissues and directly interacts

Thank you Mercedes and happy you enjoyed it😊

📣 Cell developmental state matters in B-ALL. Our study out today in ⁦Nature Cancer⁩: Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features | Nature Cancer nature.com/articles/s4301…